Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares of Stock

Key Points

• Amneal Pharmaceuticals EVP Jason Daly sold 210,000 shares at an average price of $17.40, generating $3.65 million. His remaining stake fell 85.65% to 35,171 shares.
• AMRX shares traded at $17.27, near their 52-week high of $19.26, with a $5.51 billion market capitalization and a price-to-earnings ratio of 35.24.
• Analysts maintain a positive outlook, with a consensus “Buy” rating and a $17.67 price target; institutional ownership stands at 31.82% after several funds initiated or increased positions.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) EVP Jason Daly sold 210,000 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the transaction, the executive vice president owned 35,171 shares of the company's stock, valued at approximately $611,975.40. This represents a 85.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock traded down $0.39 during trading on Thursday, hitting $17.27. 2,244,046 shares of the company's stock traded hands, compared to its average volume of 2,168,140. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. The firm's fifty day moving average price is $17.08 and its 200 day moving average price is $14.54. Amneal Pharmaceuticals, Inc. has a twelve month low of $9.15 and a twelve month high of $19.26. The company has a market cap of $5.51 billion, a PE ratio of 35.24 and a beta of 1.27.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AMRX. The Goldman Sachs Group reiterated a "buy" rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, July 12th. Zacks Research upgraded Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 7th. Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 20th. Finally, UBS Group lifted their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a "buy" rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $17.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Globeflex Capital L P bought a new stake in Amneal Pharmaceuticals during the 2nd quarter worth approximately $2,536,000. Bank of New York Mellon Corp bought a new position in Amneal Pharmaceuticals in the 2nd quarter valued at $17,573,000. Handelsbanken Fonder AB raised its position in Amneal Pharmaceuticals by 3.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 76,400 shares of the company's stock valued at $1,322,000 after purchasing an additional 2,200 shares during the last quarter. Bank of America Corp DE boosted its stake in Amneal Pharmaceuticals by 50.0% in the first quarter. Bank of America Corp DE now owns 676,795 shares of the company's stock worth $8,413,000 after purchasing an additional 225,637 shares in the last quarter. Finally, Arkadios Wealth Advisors bought a new stake in shares of Amneal Pharmaceuticals during the first quarter worth $4,165,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source